These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9690851)

  • 1. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.
    MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW
    Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
    Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
    Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).
    Hillard CJ; Manna S; Greenberg MJ; DiCamelli R; Ross RA; Stevenson LA; Murphy V; Pertwee RG; Campbell WB
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1427-33. PubMed ID: 10336536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
    Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
    Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
    Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
    Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptor agonist-stimulated [35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice.
    Basavarajappa BS; Hungund BL
    J Neurosci Res; 2001 May; 64(4):429-36. PubMed ID: 11340650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ; Brunk LK; Selley DE
    Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
    Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
    Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
    Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
    Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.
    Drew LJ; Harris J; Millns PJ; Kendall DA; Chapman V
    Eur J Neurosci; 2000 Jun; 12(6):2079-86. PubMed ID: 10886347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
    Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
    J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
    Showalter VM; Compton DR; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AM630 is an inverse agonist at the human cannabinoid CB1 receptor.
    Landsman RS; Makriyannis A; Deng H; Consroe P; Roeske WR; Yamamura HI
    Life Sci; 1998; 62(9):PL109-13. PubMed ID: 9496703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
    Zádor F; Kocsis D; Borsodi A; Benyhe S
    Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
    Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
    Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
    Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
    Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
    Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
    Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
    Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.